
The study analyzed the costs of Draf III versus standard FESS in 350 patients. Draf III procedures had higher OR and supply costs but offered potential long-term savings for patients at high risk of recurrence. When revision rates exceed 12.3%, upfront Draf III may be more cost-effective than staged revision. Findings suggest that procedure choice should consider both immediate costs and recurrence risk.
Like
Save
Share